Lifeward Secures High-Interest Bridge Loan Amidst Pending Dilutive Financing and Nasdaq Compliance Issues
Summary
Lifeward Ltd. entered into a secured promissory note for an initial $525,000 at a 24% annual interest rate, with potential for up to $1.5 million, to bridge financing ahead of a critical shareholder vote on dilutive transactions.
Key Events
-
New Secured Promissory Note
Lifeward Ltd. entered into a Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. for an initial principal amount of $525,000.
-
High Interest Rate
The note accrues interest at a rate of 24% per annum, indicating a high cost of capital.
-
Potential for Increased Funding
The principal amount may be increased by up to an additional $975,000, bringing the total potential to $1.5 million.
-
Secured by Cash
The promissory note is secured by a lien on the Company's cash.
Analysis
This 8-K filing reveals Lifeward Ltd. has secured a high-cost bridge loan from Oramed Pharmaceuticals, Inc., underscoring the company's urgent need for capital. The 24% annual interest rate and the note's security by a lien on the company's cash highlight significant financial distress. The loan's maturity is explicitly tied to the success of the pending shareholder vote on the highly dilutive Oramed acquisition and related financing, which has been a recurring theme in recent filings. This interim financing provides short-term liquidity but at a substantial cost, further complicating the company's financial position as it navigates Nasdaq compliance challenges and seeks approval for its strategic shift.
At the time of this filing, LFWD was trading at $0.52 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.50 to $2.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.